MOUNJARO 2.5MG KWIK PEN ((Tirzepatide 2.5MG)

Composition
Each prefilled pen contains Tirzepatide 2.5 mg as a sterile solution for subcutaneous injection.

Description
MOUNJARO 2.5 mg Pen is an antidiabetic injectable medicine used for the management of type 2 diabetes mellitus. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It improves glycaemic control by increasing insulin secretion, reducing glucagon release, slowing gastric emptying and decreasing appetite, thereby helping in blood sugar control and supporting weight reduction when used along with diet and exercise.

Adverse Effects
Common adverse effects may include nausea, vomiting, diarrhoea, decreased appetite, abdominal discomfort and constipation, especially during the initial phase of treatment. Injection site reactions such as redness or itching may occur. Rarely, hypoglycaemia may be seen when used with other antidiabetic medications.

Precautions
MOUNJARO is for subcutaneous use only and should not be administered intravenously or intramuscularly. Use with caution in patients with a history of pancreatitis, severe gastrointestinal disease or thyroid disorders. Dose escalation should be gradual to reduce gastrointestinal side effects. It should be used during pregnancy or breastfeeding only if clearly prescribed by a physician. Regular monitoring of blood glucose is advised during therapy.

Storage
Store refrigerated between 2°C and 8°C. Do not freeze. Protect from light. After first use, the pen may be stored as per manufacturer instructions. Keep out of reach of children.